Eikon Therapeutics, Inc. (NASDAQ:EIKN) Receives $25.20 Consensus Target Price from Brokerages

Shares of Eikon Therapeutics, Inc. (NASDAQ:EIKN) have been given a consensus rating of “Hold” by the eight research firms that are presently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $25.20.

A number of analysts recently commented on the stock. Mizuho assumed coverage on shares of Eikon Therapeutics in a research note on Monday, March 2nd. They set an “outperform” rating and a $26.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Eikon Therapeutics in a research note on Tuesday, June 2nd. Wall Street Zen cut shares of Eikon Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, April 5th. Wedbush dropped their target price on Eikon Therapeutics from $7.00 to $5.00 and set an “underperform” rating on the stock in a research report on Tuesday, May 12th. Finally, Zacks Research raised Eikon Therapeutics to a “hold” rating in a report on Friday, February 27th.

Eikon Therapeutics Price Performance

Shares of EIKN opened at $8.75 on Wednesday. Eikon Therapeutics has a fifty-two week low of $7.90 and a fifty-two week high of $17.40. The business has a 50-day moving average price of $10.20.

Eikon Therapeutics (NASDAQ:EIKN) last released its quarterly earnings data on Monday, March 30th. The company reported ($26.23) EPS for the quarter.

Eikon Therapeutics Company Profile

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.